CML & PH+ All: There is so much more to know CML & PH+ All: There is so much more to know Explore

Why is it important to think about monitoring and mutation testing when treating patients with Ph+ ALL and what is important to consider?

Think Test Treat

WHY?

  • MRD is an important prognostic factor for outcomes in Ph+ ALL1,2,5–7

WHAT?

  • Achievement of an MMR seems to be significantly prognostic for RFS7

  • Achievement of CMR at 3 months has been demonstrated to be predictive of higher long-term survival6

  • Measuring MRD early, at the end of induction therapy, can identify patients at low risk of relapse, while measuring MRD at the end of consolidation therapy identifies patients at high risk of relapse1

  • The ability to assess the potential risk of relapse using MRD helps to inform subsequent clinical decisions1

Think Test Treat

WHY?

  • Approximately 70–80% of patients with Ph+ ALL treated with 1G or 2G TKI revealed BCR-ABL1 mutations8

  • Point mutations can accumulate early in the disease course, even before treatment. While some mutant subclones persist at a low level, others expand rapidly, including mutations conferring TKI resistance9–11

  • Patients with existing mutations have a higher likelihood of developing further mutations, including compound mutations10–12

WHAT?

  • Sensitive methods of mutation detection can permit earlier identification of clinically relevant mutations that can expand and lead to TKI resistance13–15

  • There are several methods with varying sensitivities that are able to detect low-level and compound mutations, although not all are used in routine clinical practice16–19

Mutation testing methods and associated sensitivities

Conventional Sanger sequencing
15–25%
Denaturing HPLC
0.1–10%
NGS
0.5–1%
Mass spectrometry
0.05–0.5%
ASO-PCR
0.001–0.01%

Think Test Treat

WHY?

  • Based on mutation testing results, the most appropriate TKI should be selected – different TKls are effective against different mutations4

  • Choosing an inappropriate TKI leads to a high risk of subsequent treatment failure with clonal expansion of the resistant mutant and a greater likelihood of developing additional mutations, including compound mutations20,21

  • Together with T315I, compound mutations represent one of the biggest challenges in managing patients with Ph+ ALL2

WHAT?

  • Mutation testing results should inform clinical decisions4

FIND OUT MORE WITH OUR EDUCATIONAL RESOURCES

All AEs should be reported to the Global Medical Information Call Center by phone: +800 000 27423
(for local numbers see www.incyteglobalmedicalinformation.com/report-adverse-event.aspx).
Alternatively, you can report AEs by email: eumedinfo@incyte.com

For more information, please contact Incyte Medical Information: eumedinfo@incyte.com